

Sheet 1 of 3

FORM PTO-1449
MODIFIED

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
61192

SERIAL NO.
unassigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Saavedra et al.

FILING DATE
April 22, 1997

GROUP
unassigned

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,405,919	04/95	Keefer et al.			
	AB	5,250,550	10/05/93	Keefer et al.			
	AC	5,155,137	10/13/92	Keefer et al.			
	AD	5,094,815	03/10/92	Conboy et al.			
	AE	5,087,671	02/11/92	Loeppky et al.			
	AF	5,087,631	02/11/92	Shaffer et al.			
	AG	5,039,705	08/13/92	Keefer et al.			
	AH	4,985,491	01/15/91	Ohta et al.			
	AI	4,954,526	09/04/90	Keefer			
	AJ	4,952,289	08/28/90	Ciccone et al.			
	AK	4,921,683	05/01/90	Bedell			
	AL	4,708,854	11/24/87	Grinstead			
	AM	4,638,079	01/20/87	Inskip et al.			
	AN	4,482,533	11/13/84	Keith			
	AO	4,265,714	05/01/91	Nolan et al.			
	AP	3,153,094	10/10/64	Reilly			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO*
	AQ	469520	May 91	EP				
	AR	425154-A1	10/16/90	EP				
	AS	WO 89/12627	06/15/89	WIPO				
	AT	211789	07/25/84	DE				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AU	Artysbasheva et al., "Synthesis of 1-Alkoxy-3,3-Dialkyltriazene 2-Oxides from Alkoxyamines and Nitrosoamines," translates from <u>Zhurnal Organicheskoi Khimii</u> , (Journal of Organic Chemistry-U.S.S.R.), 28, (6) 1168-1173 (1987).
	AV	Bonakdar et al., "Continuous-Flow Performance of Carbon Electrodes Modified with Immobilized Fe(II)/Fe(III) Centers," <u>Calanta</u> , 36, 219-225 (1989).
	AW	DeFeudis, "Endothelium-Dependent Vasorelaxation - A New Basis for Developing Cardiovascular Drugs," <u>Drugs of Today</u> , 24 (2), 103-115 (1988).
	AX	DeLuca et al., "Parenteral Drug-Delivery Systems," in <u>Pharmaceutics and Pharmacy Practice</u> , Banker et al., eds., 238-250 (J.B. Lippincott Co., Philadelphia, PA) (1982).

*A concise statement of relevance is being submitted in lieu of a translation. 37 CFR § 1.98(b).

Sheet 2 of 3

FORM PTO-1449
MODIFIED

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
61192

SERIAL NO.
unassigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Saavedra et al.

FILING DATE
April 22, 1997

GROUP
unassigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS		
	AY	Drago, "Reactions of Nitrogen(II) Oxide," in <u>Free Radicals in Organic Chemistry</u> , Advances in Chemistry Series No. 36, 143-149 (American Chemical Society, Washington DC) (1962).
	AZ	Drago et al., "The Reaction of Nitrogen(II) Oxide with Various Primary and Secondary Amines," <u>J. Am. Chem. Soc.</u> , 83 , 1819-1822 (1961).
	BA	Furchgott, "The Role of Endothelium in the Responses of Vascular Smooth Muscle to Drugs," <u>Am. Rev. Pharmacol. Toxicol.</u> , 24 , 175-97 (1984).
	BB	Garg et al., "Nitric Oxide-Generating Vasodilators Inhibit Mitogenesis and Proliferation of Balb/C 3T3 Fibroblasts by a Cyclic GMP-Independent Mechanism," <u>Biochem. And Biophys. Res. Comm.</u> , 171 , 474-479 (1990).
	BC	Gehlen et al., "Über Reaktionen und Eigenschaften des Stickoxyds und seiner Verbindungen (II.Mitteil): Zur Kenntnis der Salze der Stickoxyd-schwefligen Säure," <u>Berichte d. D. Chem. Gesellschaft</u> , LXV , 1130-1140 (1932). ("Reactions and properties of nitric oxide compound of sulfurous acid," <u>Chemical Abstracts</u> , 26 , 4764-65.)
	BD	Hansen et al., "N-Nitrosation of Secondary Amines by Nitric Oxide via the 'Drago Complex'," in <u>N-Nitroso Compounds: Occurrence and Biological Effects</u> , IARC Scientific Publications No. 41, 21-29 (International Agency for Research on Cancer, Lyon, France) (1982).
	BE	Hibbs et al., "Nitric Oxide: A Cytotoxic Activated Macrophage Effector Molecule," <u>Biochem. And Biophys. Res. Comm.</u> , 157 , 87-94 (1988).
	BF	Holford et al., "Understanding the Dose-Effect Relationship: Clinical Application of Pharmacokinetic-Pharmacodynamic Models," <u>Clinical Pharmacokinetics</u> , 6 , 429-453 (1981).
	BG	Ignarro, "Endothelium-Derived Nitric Oxide: Actions and Properties," <u>The FASEB Journal</u> , 3 , 31-36 (1989).
	BH	Ignarro et al., "The Pharmacological and Physiological Role of a Cyclic GMP in Vascular Smooth Muscle Relaxation," <u>Ann. Rev. Pharmacol. Toxicol.</u> , 25 , 171-191 (1985).
	BI	Ignarro et al., "Mechanism of Vascular Smooth Muscle Relaxation by Organic Nitrates, Nitrites, Nitroprusside and Nitric Oxide: Evidence for the Involvement of S-Nitrosothiols as Active Intermediates," <u>J. Pharmacol. Exp. Ther.</u> , 218 , 739-749 (1981).
	BJ	Ignarro, "Nitric Oxide: A Novel Signal Transduction Mechanism for Transcellular Communication," <u>Hypertension</u> , 16 , 477-483 (1990).
	BK	Ignarro, "Biosynthesis and Metabolism of Endothelium-Derived Nitric Oxide," <u>Ann. Rev. Pharmacol. Toxicol.</u> , 30 , 535-560 (1990).
	BL	Jones, "Metastable Polymers of the Nitrogen Oxides. 1. Open Chain Nitric Oxide Analogues of Polythiazyl: A MNDO/AM1 Study," <u>J. Phys. Chem.</u> , 91 , 2588-2595 (1991).
	BM	Kruszyna et al., "Red Blood Cells Generate Nitric Oxide from Directly Acting, Nitrogenous Vasodilators," <u>Toxicol. Appl. Pharmacol.</u> , 91 , 429-438 (1987).
	BN	Kuhn et al., "Endothelium-Dependent Vasodilation in Human Epicardial Coronary Arteries: Effect of Prolonged Exposure to Glycerol Trinitrate or SIN-1," <u>J. Cardiovasc. Pharmacol.</u> , 14 (Suppl. 11), S47-S54 (1989).
	BO	Longhi et al., "Metal-Containing Compounds of the Anion (C ₂ H ₅) ₂ NN ₂ O ₂ ," <u>Inorg. Chem.</u> , 2 , 85-88 (1963).
	BP	Lutz et al., "Isolation of Trioxodinitrato (II) Complexes of Some First Row Transition Metal Ions," <u>J.C.S. Chem. Comm.</u> , 247 (1977).
	BQ	Maragos et al., "Complexes of •NO with Nucleophiles as Agents for the Controlled Biological Release of Nitric Oxide. Vasorelaxant Effects," <u>J. Med. Chem.</u> , 34 , 3242-3247 (1991).
	BR	Marletta et al., "Unraveling the Biological Significance of Nitric Oxide," <u>BioFactors</u> , 2 , 219-225 (1990).

FORM PTO-1449
MODIFIED

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
61192

SERIAL NO.
unassigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Saavedra et al.

FILING DATE
April 22, 1997

GROUP
unassigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1449DOCS (Rev. 3/6/96)

9/22/1967